Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;32(5):1195-1201.
doi: 10.1016/j.numecd.2022.01.026. Epub 2022 Jan 29.

CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy

Affiliations
Free article

CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy

Giuseppina T Russo et al. Nutr Metab Cardiovasc Dis. 2022 May.
Free article

Abstract

Background and aims: The prevalence of type 2 diabetes (T2D) in Italy is increasing and cardiovascular disease (CVD) represents the leading cause of death in this population. CAPTURE was a multinational, multicentre, non-interventional, cross-sectional study assessing the prevalence of CVD, atherosclerotic CVD (AsCVD) and CVD subtypes among patients with T2D, across 13 countries. Here we report the results from Italy.

Methods and results: Overall, 816 patients with T2D (median age, 69 years [interquartile range: 62-75]; median duration of diabetes, 11.2 years [interquartile range: 5.7-18.7]) were recruited during routine clinical visits at secondary care centres in Italy between December 2018-September 2019. The prevalence of CVD was estimated at 38.8%, largely accounted for by AsCVD (33.1%). The most prevalent CVD subtype was coronary heart disease (20.8%), followed by carotid artery disease (13.2%). Most patients (85.9%) were prescribed oral glucose-lowering agents (GLAs), particularly biguanide (76.7%). Insulin use was higher in patients with CVD (41.3%) than in patients without CVD (32.9%). Sodium-glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were prescribed to 20.2% vs 14.6%, and 14.5% vs 16.6% of patients with CVD compared to those without CVD, respectively.

Conclusion: The results show that, in Italy, more than one in three patients with T2D attending secondary care centres have CVD, 85% of whom have AsCVD, yet only a minority are treated with SGLT2is and GLP-1 RAs, in discordance with the recommendations of current national and international guidelines.

Keywords: Cardiovascular disease; Cross-sectional study; Italy; Prevalence; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest GTR: Speakers’ bureau honoraria from and advisory board membership for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi and Mundipharma. GC: No conflicts of interest to declare. FA: Speakers’ fees from Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Mundipharm and Sanofi, and consultant fees from Boehringer Ingelheim and Eli Lilly. MGC: Advisory board/speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. CB: Novo Nordisk employee and shareholder. EM: Speaking and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi; institutional research grants from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genentech, Molteni and Novo Nordisk.

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources